# Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

> **NCT01908712** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 13 (actual)

## Conditions studied

- Alpha-Mannosidosis

## Interventions

- **DRUG:** Lamazym

## Key facts

- **NCT ID:** NCT01908712
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908712, "Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01908712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*